Skip to main content
. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363

Figure 1. Flowchart of study population and assays.

Figure 1

A total of 2,787 samples sent for analysis of antinatalizumab antibodies (NAT-ab) were screened. Samples from 1,183 patients with a diagnosis of MS were evaluated for AQP4-IgG by a cell-based assay (CBA). Positive samples were retested with further CBAs and ELISAs. NMOSD was diagnosed according to the 2015 criteria. AQP4-ab = aquaporin-4 antibody; NMOSD = neuromyelitis optica spectrum disorder.